Academic anti-CD19 CAR-T for relapsed or refractory large B‑cell lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational study of adults with relapsed or refractory large B‑cell lymphoma treated at the N.N. Alexandrov National Cancer Centre in Belarus using an academic anti‑CD19 CAR‑T product manufactured with a lentiviral vector. Participants must have CD19‑positive tumor tissue and prior exposure to at least one line of anti‑tumor therapy, and patients with active hepatitis B/C, HIV, pregnancy, or very low naïve T‑cell counts are excluded. The study will collect real‑world safety and efficacy outcomes after administration of the academic CAR‑T product without randomization. Results will help compare clinical outcomes and tolerability of this locally produced CAR‑T approach to existing commercial therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* age ≥18 years,
* relapsed or refractory LBCL,
* confirmed CD19 expression in tumor tissue,
* prior exposure to at least one line of anti-tumor therapy

Exclusion Criteria:

* pregnancy,
* active hepatitis B or C infection, HIV infection,
* naïve T-lymphocyte count (CD3+CCR7+CD45RO-) ≤ 0,5%

Where it's running

• NN Alexandrov National Cancer Centre of Belarus
  Lyasny, Minsk Oblast, Belarus Recruiting

Study contacts

• Study coordinator: Natalya Konoplya, PhD, MD, Professor
• Email: NKonoplya@mail.ru
• Phone: +375297723101

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• Adding CLS-015 to anti-CD19 CAR-T therapy for large B‑cell lymphoma during lymphodepletion

  This trial tests whether giving CLS-015 (an enzyme that breaks down NETs) alongside anti‑CD19 CAR‑T therapy helps adults with large B‑cell lymphoma who have stable or progressing disease at the time of lymphodepletion.

  Recruiting Phase 1 Tel-Aviv Sourasky Medical Center · Tel Aviv · NCT07361224

• CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma

  This trial tries CD5 CAR T-cell therapy, using either the patient's own cells or donor cells, and may bridge to stem-cell transplant for people 14–70 with relapsed or refractory T-cell lymphoma.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing and 2 other locations · NCT07022964

• Glofitamab plus obinutuzumab for mantle cell lymphoma after CAR‑T

  This trial tests whether the antibody drug glofitamab given with obinutuzumab can shrink or control mantle cell lymphoma that returned or didn't respond after CD19 CAR‑T therapy in adults.

  Recruiting at 11 sites Phase 2 National Cancer Institute (NCI) · Duarte, California and 10 other locations · NCT07003295

• CD7 CAR T-Cell Therapy for T-Cell Lymphomas

  This study is testing a new CAR T-cell therapy for people with T-cell lymphomas that haven't responded to regular treatments to see if it is safe and effective.

  Recruiting at 4 sites Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 3 other locations · NCT06925464

• Using golcadomide and rituximab to prepare patients for CAR T-cell therapy in aggressive B-cell lymphoma

  This study is testing if a combination of golcadomide and rituximab can help patients with aggressive B-cell lymphoma get ready for CAR T-cell therapy.

  Recruiting at 7 sites Phase 2 Mayo Clinic · Scottsdale, Arizona and 6 other locations · NCT06834373

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.